---
layout: post
title: New Drug Approvals 2011 - Part XII Abiraterone Acetate  (ZytigaTM)
date: '2011-05-01T13:25:00.013+01:00'
author: Bissan Al-Lazikani
tags:
- 2011 New Drugs
- Small Molecule Drugs
- Natural Product Drugs
- Prodrugs
modified_time: '2012-01-04T08:56:40.923Z'
thumbnail: http://2.bp.blogspot.com/-ZBs1-vwoNpU/TdJl-bZaGtI/AAAAAAAABI0/l8MZ12KSYS0/s72-c/zytiga_163023_163024.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-2553319315228882713
blogger_orig_url: http://chembl.blogspot.com/2011/05/new-drug-approvals-2011-part-xi.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-ZBs1-vwoNpU/TdJl-bZaGtI/AAAAAAAABI0/l8MZ12KSYS0/s1600/zytiga_163023_163024.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://2.bp.blogspot.com/-ZBs1-vwoNpU/TdJl-bZaGtI/AAAAAAAABI0/l8MZ12KSYS0/s1600/zytiga_163023_163024.jpg" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<br />
<br />
<br />
<center><img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/7,0,1,1,0,0,1,1,0" width="400px" /></center><center><br />
</center>   <br />
<div style="text-align: center;">
<b>  ATC code (partial): G03</b>&nbsp;</div>
<br />
On 28th April 2011, the FDA approved  Abiraterone acetate (Brand name <a href="http://www.trademarkia.com/trademarks-search.aspx?tn=zytiga">Zytiga</a><sup>TM</sup>, NDA 202379) for the treatment of castrate-resistant prostate cancer (CRPC). Specifically, it is indicated for use in combination with prednisone for the treatment of patients with metastatic CRPC who have received prior chemotherapy containing docetaxel. Response biomarkers are amplified Androgen Receptor (AR); PTEN loss and hormone driven ERG rearrangement.<br />
<br />
Abiraterone acetate (research code: CB-7630)  is a steroid derivative with a chemical formula C26H33NO, (IUPAC: (3β)­ 17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate; SMILES= (CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c5cccnc5)[C@@H]3CC=C2C1 ); InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1). It has molecular weight 391.55 and a LogP of 5.12. Abiraterone acetate is an ester <a href="http://en.wikipedia.org/wiki/Prodrug">prodrug</a> which is converted <i>in vivo</i> to the active component, abiraterone.    <a href="http://4.bp.blogspot.com/-fHEGHG2zOkc/Tb08qwdtmdI/AAAAAAAAAE4/2xsFc3PhkQM/s1600/Abiraterone_tpactive.png"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5601700216780462546" src="http://4.bp.blogspot.com/-fHEGHG2zOkc/Tb08qwdtmdI/AAAAAAAAAE4/2xsFc3PhkQM/s400/Abiraterone_tpactive.png" style="cursor: hand; cursor: pointer; display: block; height: 113px; margin: 0px auto 10px; text-align: center; width: 400px;" /></a><br />
<br />
Abiraterone acetate: (ChEMBLID:<a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/538435">538435</a>; canSAR <a href="https://cansar.icr.ac.uk/index.php?autologin=guest&amp;redirect=creport&amp;redirect_value=506173">link</a>)  Abiraterone: (ChEMBLID:<a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/522175">522175</a>; canSAR: <a href="https://cansar.icr.ac.uk/index.php?autologin=guest&amp;redirect=creport&amp;redirect_value=181093">link</a>).&nbsp;Abiratrone has a terminal half-life (T<sub>1/2</sub>) of 12 (±5) hours.<br />
<br />
Abiraterone irreversibly inhibits  17-α-hydroxylase/C17,20-lyase (CYP17A1), an androgen biosynthesis enzyme expressed in testicular, adrenal, and prostatic tumor tissue.  (Uniprot:<a href="http://www.uniprot.org/uniprot/P05093">P05093</a>, canSAR <a href="https://cansar.icr.ac.uk/index.php?autologin=guest&amp;redirect=treport&amp;redirect_value=P05093">link</a>)  and a member of the cytochrome P450 family of enzymes (PFAM:<a href="http://pfam.sanger.ac.uk/family/p450">P450</a>). Cyp17A1 normally catalyses a two step reaction: the conversion of <a href="http://en.wikipedia.org/wiki/Pregnenolone">pregnenolone</a> and <a href="http://en.wikipedia.org/wiki/Progesterone">progesterone</a> to their 17α-hydroxy- derivatives and then the formation of <a href="http://en.wikipedia.org/wiki/Dehydroepiandrosterone">dehydroepiandrosterone</a> (DHEA) and <a href="http://en.wikipedia.org/wiki/Androstenedione">androstenedione</a>, the precursors of <a href="http://en.wikipedia.org/wiki/Testosterone">testosterone</a>. No structure of CYP17A1 itself exists, but it is homologous to other <a href="http://en.wikipedia.org/wiki/Cytochrome_p450">Cytochrome p450</a> enzymes such as CYP1A2 (PDBe:<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/2hi4/summary.html">2hi4</a>).<br />
<a href="http://2.bp.blogspot.com/-TLVd9wKxtwU/Tb1N6hbsrQI/AAAAAAAAAFA/9NcW53-jgh4/s1600/Cyp1A2.png"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5601719179321060610" src="http://2.bp.blogspot.com/-TLVd9wKxtwU/Tb1N6hbsrQI/AAAAAAAAAFA/9NcW53-jgh4/s400/Cyp1A2.png" style="display: block; height: 350px; margin-bottom: 10px; margin-left: auto; margin-right: auto; margin-top: 0px; text-align: center; width: 341px;" /></a>  Abiraterone's safety and effectiveness were established in a clinical study of 1,195 patients with late-stage castration-resistant prostate cancer who had received prior treatment with docetaxel chemotherapy, and showed improved survival. Zytiga is supplied in 250 mg tablets and the recommended dose  is 1000 mg administered orally once daily in combination with prednisone 5 mg administered orally twice daily.<br />
<br />
The prescribing information can be found <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf">here</a>.<br />
<br />
Abiraterone was discovered at the <a href="http://www.icr.ac.uk/">Institute of Cancer Research</a> and, through a series of licensing and aquisitions is now manufactered and marketed by <a href="http://www.centocororthobiotech.com/cobi/viewDocumentByTitleAlias.html?title=PR_042811">Entocor Ortho Biotech Inc</a>, part of Johnson and Johnson.